Autosomal Recessive Optic Atrophy, OPA7 Type (TMEM126A): A Comprehensive Disease Report

MONDO: MONDO:0013069 · OMIM phenotype: #612989 · OMIM gene: 612988 (TMEM126A) · Locus: 11q14.1 · Category:* Mendelian (autosomal recessive)

Summary

Autosomal recessive optic atrophy OPA7 type is an ultra-rare, early-onset, bilateral, progressive mitochondrial optic neuropathy caused by biallelic loss-of-function variants in TMEM126A on chromosome 11q14.1. It was the first gene identified for nonsyndromic autosomal recessive optic atrophy, discovered by homozygosity mapping and positional cloning in a large consanguineous Algerian family and additional families from the Maghreb, all carrying a recurrent nonsense founder allele, c.163C>T; p.Arg55* (R55X) (PMID: 19327736). Until this discovery the very existence of nonsyndromic recessive optic atrophy had been disputed (PMID: 22815638).

Mechanistically, TMEM126A is an inner mitochondrial membrane assembly factor for the ND4 distal membrane module of respiratory chain complex I (NADH:ubiquinone oxidoreductase). Its loss produces an isolated complex I deficiency, established by two independent 2021 studies (PMID: 33879611; PMID: 33882309). The resulting bioenergetic failure and increased reactive oxygen species (ROS) selectively injure retinal ganglion cells (RGCs) and their optic-nerve axons — the cell type most vulnerable to perturbed mitochondrial homeostasis — producing the optic-atrophy phenotype shared across the hereditary optic neuropathies (PMID: 36155660). Because the lesion is a complex I defect, OPA7 is bioenergetically analogous to Leber hereditary optic neuropathy (LHON), which is caused by mtDNA complex I subunit mutations.

Clinically, OPA7 presents in childhood (sometimes congenitally, occasionally in adolescence) with bilateral optic disc pallor, reduced visual acuity, central/centrocecal scotoma, and dyschromatopsia; a subset of patients have auditory neuropathy and/or peripheral sensory-motor neuropathy, defining a syndromic tail to the phenotype (PMID: 20405026; PMID: 22815638). There is no OPA7-specific therapy; care is supportive (low-vision aids, hearing rehabilitation, genetic counseling), with idebenone and AAV gene therapy as mechanism-based prospects extrapolated — not yet validated — from LHON.

Key Findings

Finding 1 — TMEM126A is the causal gene, with a Maghreb founder mutation

Whole-genome homozygosity mapping combined with positional cloning in a large consanguineous Algerian family, followed by confirmation in three additional Maghreb families, identified TMEM126A (chr 11q14.1; OMIM gene 612988; phenotype OPA7 #612989) as the first gene responsible for nonsyndromic autosomal recessive optic atrophy (PMID: 19327736). The authors state they "identified the first gene, to our knowledge, responsible for this condition, TMEM126A, in a large multiplex inbred Algerian family and subsequently in three other families originating from the Maghreb."*

The recurrent founder allele is the nonsense variant c.163C>T; p.Arg55* (R55X). An independent Moroccan family was later found to carry the identical R55X allele, and haplotype analysis was "consistent with a single ancestral origin" (PMID: 22815638) — confirming a North-African (Maghreb) founder effect. This founder architecture explains why the disease clusters in consanguineous populations of North-African ancestry.

Finding 2 — TMEM126A is a mitochondrial complex I assembly factor for the ND4 module

Two independent 2021 studies established the molecular function of TMEM126A. Formosa et al. showed that "loss of TMEM126A results in an isolated complex I deficiency" and that "TMEM126A is involved in the assembly of the ND4 distal membrane module of complex I," associating with the newly synthesized mtDNA-encoded ND4 subunit (PMID: 33879611). This is functionally distinct from its paralogue TMEM126B, which assembles the ND2 module.

In parallel, D'Angelo et al. demonstrated that during complex I disassembly "the ND4 module remains stable and bound to TMEM126A," concluding that they "uncover the function of TMEM126A, the product of a disease gene causing recessive optic atrophy, as a factor necessary for the correct assembly and function of CI" (PMID: 33882309). Earlier work had localized the protein to the inner mitochondrial membrane cristae (PMID: 23500070: "encode an inner mitochondrial membrane associated cristae protein"), consistent with a role at the site of oxidative phosphorylation.

Together these establish the upstream molecular lesion: TMEM126A loss → failure to assemble the ND4 distal membrane module → isolated complex I deficiency.

Finding 3 — Phenotype: early-onset bilateral progressive optic atrophy with variable auditory and peripheral neuropathy

The core phenotype is bilateral optic atrophy — temporal or diffuse optic disc pallor, reduced visual acuity, central/centrocecal scotoma, and dyschromatopsia — with childhood onset. Meyer et al. reported a consanguineous R55X family in which "both affected subjects had poor vision from birth and complained of progressive visual loss over time," with bilateral temporal optic nerve pallor, normal full-field ERG (excluding a primary photoreceptor process), and grossly abnormal pattern VEPs indicating RGC/optic-nerve dysfunction. Crucially, "audiological investigation in both siblings revealed abnormalities falling within the auditory neuropathy/dysynchrony spectrum," defining a syndromic (optic atrophy + auditory neuropathy) form (PMID: 20405026).

Expressivity is variable. Désir et al. described a Moroccan family with a "relatively mild clinical course, with sudden onset in adolescence in the proband," and noted that "the proband, but not the other affected siblings, had sensory-motor axonal neuropathy" with demyelinating features — extending the syndromic spectrum to peripheral neuropathy. A heterozygous carrier in that family exhibited exercise-induced transient visual loss (Uhthoff's phenomenon) (PMID: 22815638). Kloth et al. reported relatively mild, non-syndromic disease in Turkish and Iraqi families (PMID: 30961538).

Finding 4 — Mutation spectrum extends beyond the R55X founder allele

Beyond the recurrent R55X nonsense founder allele in Maghrebian families, Kloth et al. identified pathogenic/likely pathogenic variants in non-Maghreb individuals, noting: "To date, all reports of pathogenic TMEM126A variants are from affected individuals of Maghrebian origin, who all carry an identical nonsense variant. Here we report two novel variants in the TMEM126A gene from non-Maghreb individuals" (PMID: 30961538). These are a homozygous splice-donor variant c.86+2T>C in a Turkish patient (producing an exon-2-skipped functional null transcript) and a homozygous missense p.Ser36Leu (S36L) in Iraqi siblings, affecting a highly conserved residue and ultra-rare in population databases. TMEM126A is among the top 10 nuclear genes accounting for hereditary optic neuropathy diagnoses in a 2,186-proband cohort (PMID: 36317462).

Finding 5 — OPA7 belongs to the mitochondrial optic neuropathies; RGCs are selectively vulnerable

Reviews of hereditary optic neuropathies establish a unifying mitochondrial pathophysiology: "A unifying feature in the pathophysiology of these disorders appears to involve mitochondrial dysfunction, suggesting that the retinal ganglion cells and their axons are especially susceptible to perturbations in mitochondrial homoeostasis" (PMID: 36155660). OPA7/TMEM126A joins OPA1 (dominant optic atrophy), the mtDNA complex I genes of LHON (MT-ND1/4/6), ACO2, RTN4IP1, SPG7, AFG3L2, MFN2, WFS1, FDXR, and NR2F1 among nuclear-gene-panel causes; these 10 genes account for ~96% of autosomal optic neuropathy diagnoses in the 2,186-proband cohort (PMID: 36317462). Because TMEM126A loss causes isolated complex I deficiency, OPA7 shares the LHON-type complex-I bioenergetic lesion.

Finding 6 — Ultra-rare AR disorder with complete penetrance, variable expressivity, and strong consanguinity/founder component

Nonsyndromic autosomal recessive optic atrophy is described as "extremely rare and its existence was disputed" (PMID: 22815638); reports remain "sparse" with only a handful of families worldwide (PMID: 30961538). Inheritance is autosomal recessive (biallelic TMEM126A); reported families are consanguineous (Algerian, Moroccan, Pakistani, Turkish, Iraqi). Affected homozygotes are consistently symptomatic (complete penetrance for optic atrophy), whereas heterozygous carriers are generally unaffected — with the noted exception of a single carrier showing transient exercise-induced visual loss. Expressivity is variable in age of onset (congenital to adolescence) and in syndromic features (isolated optic atrophy vs. added auditory/peripheral neuropathy).

Finding 7 — No OPA7-specific therapy; supportive care with idebenone/gene therapy as mechanism-based prospects

There is no approved disease-specific or curative treatment for OPA7. Management is supportive: low-vision aids and visual rehabilitation, hearing aids or cochlear implantation where auditory neuropathy is present, and genetic counseling. Because OPA7 shares the complex-I bioenergetic lesion of LHON, idebenone — a synthetic CoQ10 analogue — is a plausible but not OPA7-validated candidate. Its mechanism is described as: "Idebenone, a synthetic CoQ derivative, is a potent intramitochondrial antioxidant and can shuttle electrons directly to complex III of the respiratory chain, thereby bypassing complex I deficiency" (PMID: 39963374). In LHON, a meta-analysis found a favorable effect: "The overall mean LogMAR difference was -0.32 (95% CI: -0.50 to -0.15), with a favorable effect of idebenone" (PMID: 40653811). AAV gene-replacement (e.g., lenadogene nolparvovec for MT-ND4 LHON) provides proof-of-concept for optic-neuropathy gene therapy, but no OPA7 program exists (PMID: 39704163).

Mechanistic Model / Interpretation

Ordered causal chain (initiating lesion → clinical manifestation)

1. Biallelic loss-of-function variant in TMEM126A (most commonly p.Arg55* nonsense; also splice-donor c.86+2T>C and missense p.Ser36Leu) → absence or dysfunction of the TMEM126A protein at the inner mitochondrial membrane cristae. [Demonstrated — human genetics, PMID 19327736, 22815638, 30961538]
2. Loss of TMEM126A → failure to assemble the ND4 distal membrane module of complex I. TMEM126A normally binds the newly synthesized mtDNA-encoded ND4 subunit and chaperones its incorporation. [Demonstrated — cell biology, PMID 33879611, 33882309]
3. Failed ND4-module assembly → isolated complex I (NADH:ubiquinone oxidoreductase) deficiency. [Demonstrated — PMID 33879611]
4. Complex I deficiency → impaired oxidative phosphorylation (reduced NADH oxidation, reduced proton pumping, reduced ATP synthesis) and increased reactive oxygen species. [Inferred for OPA7 by analogy to LHON complex-I lesions; established for the shared mechanism class, PMID 36155660]
5. Bioenergetic failure + oxidative stress → selective injury of retinal ganglion cells and their long, energy-demanding pre-laminar axons. [Demonstrated as a unifying mechanism of mitochondrial optic neuropathies, PMID 36155660]
6. RGC/axonal degeneration → bilateral, progressive optic atrophy (disc pallor, reduced acuity, central/centrocecal scotoma, dyschromatopsia). [Demonstrated clinically, PMID 20405026]
7. Branch A: In a subset, the same bioenergetic vulnerability of specialized neurons → auditory neuropathy/dysynchrony. [Demonstrated, PMID 20405026]
8. Branch B: In a subset, → peripheral sensory-motor axonal neuropathy with demyelinating features. [Demonstrated, PMID 22815638]

Diagram

 TMEM126A biallelic LoF (R55X / c.86+2T>C / S36L)
 │
 ▼
 Loss of inner-membrane cristae assembly factor
 │
 ▼
 ND4 distal membrane module fails to assemble  ── (paralogue TMEM126B → ND2 module, unaffected)
 │
 ▼
 Isolated Complex I (NADH:ubiquinone oxidoreductase) deficiency
 │
┌────────┴────────┐
▼                 ▼
   ↓ ATP synthesis     ↑ ROS / oxidative stress
└────────┬────────┘
 ▼
 Selective RGC + optic-nerve axon degeneration (high energy demand)
 │
     ┌───────────┼───────────────┐
     ▼           ▼               ▼
 Optic atrophy  Auditory        Peripheral
 (core)         neuropathy      neuropathy
(subset)        (subset)

Upstream vs downstream

• Upstream (genetic/molecular): TMEM126A loss; failed ND4-module assembly; complex I deficiency.
• Downstream (cellular/clinical): ATP depletion, ROS accumulation, RGC apoptosis/axonal loss, optic atrophy, and the variable auditory/peripheral neuropathy branches.

Ontology term suggestions

Section-by-Section Detail

1. Disease Information

OPA7 is a nonsyndromic (with a syndromic tail) autosomal recessive mitochondrial optic neuropathy characterized by early-onset, bilateral, progressive degeneration of retinal ganglion cells and the optic nerve. Identifiers: MONDO:0013069; OMIM phenotype #612989; OMIM gene 612988; locus 11q14.1; Orphanet lists it under nonsyndromic/recessive optic atrophy. Synonyms: OPA7; optic atrophy 7; TMEM126A-related optic atrophy; autosomal recessive optic atrophy, TMEM126A type. Information is derived from aggregated disease-level resources* and small consanguineous-family case series (not EHR/individual-patient registries).

2. Etiology

Primary cause: biallelic (homozygous or compound heterozygous) loss-of-function variants in TMEM126A (genetic, Mendelian). Genetic risk factors: the R55X founder allele in Maghreb populations; consanguinity dramatically raises the risk of homozygosity. Environmental risk/protective factors and gene–environment interactions: none established for OPA7 specifically; by analogy to LHON, mitochondrial toxins (tobacco, alcohol) and oxidative stressors are theoretical exacerbators but unproven here. No protective alleles are documented.

3. Phenotypes

Core: bilateral optic atrophy (HP:0000648), reduced visual acuity (HP:0007663), central/centrocecal scotoma (HP:0000603), dyschromatopsia (HP:0000551), temporal/diffuse optic disc pallor. Onset ranges from congenital/childhood to occasionally adolescence; course is progressive; penetrance for optic atrophy is complete in homozygotes. Variable syndromic features: auditory neuropathy/dysynchrony (HP:0031604) and peripheral sensory-motor axonal neuropathy (HP:0003477). Quality-of-life impact is substantial and lifelong (low vision/legal blindness affecting central vision, education, employment, mobility); where hearing is involved, communication is additionally affected. Disease-specific QoL instruments have not been reported for OPA7.

4. Genetic/Molecular Information

Causal gene: TMEM126A (HGNC:25382; NCBI Gene 84233; 11q14.1). Pathogenic variants: c.163C>T p.(Arg55*) nonsense (founder, Maghreb); c.86+2T>C splice-donor (Turkish); c.107C>T p.(Ser36Leu) missense (Iraqi). Classification: pathogenic/likely pathogenic per ACMG; nonsense and splice alleles are functional nulls; the missense affects a highly conserved residue and is ultra-rare in gnomAD. Origin: germline. Functional consequence: loss of function (failed complex I ND4-module assembly). No modifier genes, epigenetic changes, or chromosomal abnormalities are established for OPA7.

5. Environmental Information

No environmental, lifestyle, or infectious contributors are established. This is a monogenic disorder; environmental factors are, at most, theoretical modifiers extrapolated from mitochondrial optic-neuropathy biology.

6. Mechanism / Pathophysiology

See the ordered causal chain and diagram above. Key pathway: mitochondrial respiratory chain complex I assembly (GO:0032981) at the inner mitochondrial membrane/cristae (GO:0005743/GO:0030061); downstream oxidative phosphorylation failure and oxidative stress; cellular process is RGC apoptosis/axonal degeneration. Cell type: retinal ganglion cell (CL:0000740).

7. Anatomical Structures Affected

Primary organ: eye — specifically retina (UBERON:0000966) and optic nerve (UBERON:0000941); body system: nervous/visual. Secondary: auditory nerve/spiral ganglion (auditory neuropathy) and peripheral nerves (peripheral neuropathy). Tissue/cell: neural tissue; retinal ganglion cells (CL:0000740). Subcellular: mitochondrial inner membrane/cristae (GO:0005743/GO:0030061). Lateralization: bilateral (typically symmetric).

8. Temporal Development

Onset: congenital/pediatric, occasionally adolescent; insidious to sometimes sudden. Progression: slowly progressive over years; chronic and lifelong; no spontaneous remission. Critical period: RGC loss is presumed irreversible once established, so any future neuroprotective/gene therapy would need early intervention (as demonstrated for idebenone in LHON, PMID 39704163).

9. Inheritance and Population

Inheritance: autosomal recessive. Penetrance: complete in homozygotes. Expressivity: variable (onset age; syndromic features). Founder effect: North-African (Maghreb) R55X of single ancestral origin. Consanguinity: central to disease occurrence. Epidemiology: ultra-rare (no reliable prevalence/incidence; only a handful of families worldwide). Populations: Algerian, Moroccan, Turkish, Iraqi, Pakistani consanguineous families. Sex ratio: no sex bias expected (autosomal recessive), consistent with reported affected siblings of both sexes.

10. Diagnostics

Clinical: ophthalmologic exam (visual acuity, color vision, visual fields showing central/centrocecal scotoma, fundoscopy showing optic disc pallor), OCT (RNFL/ganglion cell layer thinning), pattern VEP (abnormal, indicating RGC/optic-nerve dysfunction), full-field ERG (typically normal, excluding retinopathy). Audiology (ABR/OAE pattern of auditory neuropathy) and nerve conduction studies where syndromic features are suspected. Genetic testing is definitive: targeted TMEM126A sequencing, hereditary-optic-neuropathy gene panels, WES/WGS; mtDNA LHON testing to exclude the main differential. Differential diagnosis: LHON (maternal inheritance, mtDNA complex I mutations), OPA1 dominant optic atrophy, ACO2, RTN4IP1, WFS1 (Wolfram), and syndromic causes.

11. Outcome/Prognosis

Vision loss is chronic, bilateral, and generally progressive, leading to significant permanent visual impairment; the disorder is not life-limiting by itself. Morbidity is driven by low vision (± hearing loss, ± peripheral neuropathy). No validated prognostic biomarkers exist; earlier onset and syndromic features suggest greater burden. Recovery potential is limited given irreversible RGC loss.

12. Treatment

No OPA7-specific or curative therapy. Supportive/rehabilitative: low-vision aids, visual and occupational rehabilitation, hearing aids/cochlear implantation for auditory neuropathy, physiotherapy for peripheral neuropathy, genetic counseling. Mechanism-based prospects (extrapolated from LHON, not OPA7-validated): idebenone (NCIT synthetic CoQ analogue; bypasses complex I to complex III, antioxidant), and AAV gene-replacement/allotopic-expression approaches. Personalized/genotype-guided therapy is not yet available.

13. Prevention

No primary prevention beyond genetic counseling and carrier/cascade testing in at-risk consanguineous families. Prenatal or preimplantation genetic testing is feasible once the familial variant is known. Secondary/tertiary prevention focuses on early rehabilitation and management of syndromic complications. No immunization or public-health measures apply.

14. Other Species / Natural Disease

TMEM126A is evolutionarily conserved with orthologues in mouse (Tmem126a), zebrafish, and other vertebrates, and functions in complex I assembly across species. No well-characterized naturally occurring animal disease has been reported for OPA7 specifically; comparative pathology draws on the broader mitochondrial-optic-neuropathy literature. Zoonotic/cross-species transmission is not applicable (monogenic disorder).

15. Model Organisms

Cellular models (patient fibroblasts, gene-edited/knockdown human cell lines) were central to defining TMEM126A's complex-I ND4-module assembly role (PMID 33879611, 33882309). For the disease class, iPSC-derived retinal organoids reproduce RGC/axonal loss and respond to idebenone in the related LHON context (PMID 41019299), providing a template platform adaptable to OPA7. Dedicated Tmem126a knockout animal models with full OPA7 phenotype recapitulation are not prominently reported; developing an RGC-degeneration model that also captures the auditory/peripheral branches is an open need.

Evidence Base

Supporting/contextual literature includes RTN4IP1-related recessive optic neuropathy (PMID 26593267), reviews of mitochondrial eye disease (PMID 28481993), dominant optic atrophy/OPA1 biology (PMID 33340656), advanced therapies for inherited optic neuropathies (PMID 41318849), and iPSC retinal-organoid LHON models (PMID 41019299).

Limitations and Knowledge Gaps

• Extreme rarity: Only a handful of families worldwide; no population-based prevalence/incidence, natural-history, or QoL data exist. All clinical characterization derives from small consanguineous case series.
• Genotype–phenotype correlations are underpowered: Whether R55X, splice, or missense alleles differ systematically in severity or syndromic penetrance is unknown.
• Mechanistic gap for OPA7 specifically: The ATP-depletion/ROS/RGC-apoptosis steps are inferred by analogy to LHON; OPA7 patient-derived RGC/organoid studies quantifying bioenergetic and ROS phenotypes are lacking.
• No OPA7 therapy evidence: Idebenone and gene therapy benefits are extrapolated from LHON; no OPA7 trial or even case-level treatment outcome data are available.
• No dedicated animal model with full OPA7 (optic + auditory + peripheral) recapitulation is well established.
• Modifiers, epigenetics, and environmental interactions are entirely uncharacterized.

Proposed Follow-up Experiments / Actions

1. Build an OPA7 iPSC → retinal-organoid model from patient fibroblasts (R55X and non-founder alleles), quantifying RGC number, axonal density, mitochondrial membrane potential, ATP, complex I activity, and ROS — mirroring the LHON-RO paradigm (PMID 41019299) — and test idebenone rescue.
2. Genotype–phenotype registry: Aggregate all known families to correlate allele type with onset, progression, and syndromic-feature penetrance (auditory/peripheral).
3. Generate a Tmem126a knockout/knock-in mouse or zebrafish and phenotype RGC loss, VEP/ABR, and nerve conduction to test whether the syndromic branches are recapitulated.
4. Deep bioenergetic characterization of patient fibroblasts (Seahorse respirometry, BN-PAGE complex I assembly intermediates) to confirm the ND4-module assembly defect across disease alleles beyond R55X.
5. Compassionate-use / n-of-1 idebenone trials in OPA7 patients with structured OCT/visual-acuity endpoints, given the shared complex-I lesion and favorable LHON meta-analysis effect size.
6. Explore AAV-mediated TMEM126A gene replacement as a preclinical program, leveraging the lenadogene-nolparvovec optic-neuropathy delivery precedent.
7. Carrier-screening and cascade-testing programs in high-consanguinity North-African/Middle-Eastern communities to enable early counseling and future early intervention.

Report compiled from 7 confirmed findings and 35 reviewed papers over 5 investigation iterations. Evidence types span human genetics/clinical case series, cell-biology functional studies, cohort analyses, and LHON-derived therapeutic meta-analyses. Claims are attributed only to the abstracts/citation snippets verified during the investigation.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0031604 (2 mentions) - the report calls it "auditory neuropathy"; HP calls it Agenesis of the carotid canal

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• UBERON:0000941 (2 mentions) - the report calls it "optic nerve"; UBERON calls it cranial nerve II, and lists "optic nerve" among its other names
• HP:0000551 (2 mentions) - the report calls it "dyschromatopsia / color vision defect"; HP calls it Color vision defect